NASDAQ:HBIO - Harvard Bioscience Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.45 +0.15 (+3.49 %)
(As of 05/25/2018 06:06 AM ET)
Previous Close$4.30
Today's Range$4.20 - $4.50
52-Week Range$2.30 - $6.15
Volume126,172 shs
Average Volume115,621 shs
Market Capitalization$154.72 million
P/E Ratio89.00
Dividend YieldN/A
Beta1.27

About Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience logoHarvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999

Debt

Debt-to-Equity Ratio0.78
Current Ratio2.50
Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio89.00
Forward P/E Ratio44.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$101.88 million
Price / Sales1.57
Cash Flow$0.1698 per share
Price / Cash26.21
Book Value$2.20 per share
Price / Book2.02

Profitability

EPS (Most Recent Fiscal Year)$0.05
Net Income$-860,000.00
Net Margins-3.70%
Return on Equity2.79%
Return on Assets1.75%

Miscellaneous

Employees434
Outstanding Shares35,980,000

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.03. The medical instruments supplier had revenue of $26.76 million for the quarter, compared to analysts' expectations of $27.50 million. Harvard Bioscience had a negative net margin of 3.70% and a positive return on equity of 2.79%. View Harvard Bioscience's Earnings History.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Harvard Bioscience.

What price target have analysts set for HBIO?

2 equities research analysts have issued twelve-month price objectives for Harvard Bioscience's shares. Their forecasts range from $8.00 to $10.00. On average, they expect Harvard Bioscience's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Harvard Bioscience.

Who are some of Harvard Bioscience's key competitors?

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the folowing people:
  • Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 52)
  • Mr. Robert E. Gagnon, CFO & Treasurer (Age 44)
  • Mr. Yong Sun, VP of Commercial Operations (Age 54)
  • Mr. Corey Manchester, Director of Fin. & Investor Relations

Has Harvard Bioscience been receiving favorable news coverage?

Headlines about HBIO stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Harvard Bioscience earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (15.12%), Dimensional Fund Advisors LP (5.24%), Heartland Advisors Inc. (4.36%), BlackRock Inc. (4.01%), Segall Bryant & Hamill LLC (2.78%) and Foundry Partners LLC (1.83%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

Which major investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Heartland Advisors Inc., Foundry Partners LLC, Ancora Advisors LLC, BlackRock Inc., Spark Investment Management LLC, GSA Capital Partners LLP and Bard Associates Inc.. Company insiders that have sold Harvard Bioscience company stock in the last year include George Uveges, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

Which major investors are buying Harvard Bioscience stock?

HBIO stock was bought by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, ARS Investment Partners LLC, Millennium Management LLC, Segall Bryant & Hamill LLC, Dimensional Fund Advisors LP, Municipal Employees Retirement System of Michigan, Wedge Capital Management L L P NC and Algert Global LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $4.45.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $154.72 million and generates $101.88 million in revenue each year. The medical instruments supplier earns $-860,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Harvard Bioscience employs 434 workers across the globe.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]


MarketBeat Community Rating for Harvard Bioscience (HBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Harvard Bioscience (NASDAQ:HBIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Harvard Bioscience in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 102.25%. The high price target for HBIO is $10.00 and the low price target for HBIO is $8.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00N/A
Price Target Upside: 102.25% upside60.71% upside106.90% upsideN/A

Harvard Bioscience (NASDAQ:HBIO) Consensus Price Target History

Price Target History for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ:HBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018BenchmarkSet Price TargetBuy$10.00HighView Rating Details
1/24/2018Janney Montgomery ScottBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.00LowView Rating Details
11/17/2016Singular ResearchInitiated CoverageBuy$5.50N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Harvard Bioscience (NASDAQ:HBIO) Earnings History and Estimates Chart

Earnings by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ:HBIO) Earnings Estimates

Current Year EPS Consensus Estimate: $0.1 EPS
Next Year EPS Consensus Estimate: $0.16 EPS

Harvard Bioscience (NASDAQ HBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.05N/AView Earnings Details
5/2/2018Q1 2018$0.03$0.03$27.50 million$26.76 millionViewListenView Earnings Details
3/1/2018Q4 2017$0.05$0.05$26.60 million$27.46 millionViewListenView Earnings Details
10/26/2017Q3 2017$0.03$0.03$24.60 million$25.05 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.03$0.01$24.00 million$25.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016$0.04$0.01$26.90 million$26.42 millionViewListenView Earnings Details
10/27/2016Q3$0.01$0.01$26.00 million$25.01 millionViewListenView Earnings Details
7/28/2016Q2$0.03$0.03$26.60 million$26.10 millionViewListenView Earnings Details
5/12/2016Q1$0.02$0.05$26.00 million$27.00 millionViewListenView Earnings Details
4/29/2016Q4$0.03$0.03$28.37 millionViewN/AView Earnings Details
10/29/2015Q315$0.05$0.03$27.01 million$25.70 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.05$26.60 million$28.80 millionViewListenView Earnings Details
4/30/2015Q414$0.05$0.01$27.15 million$25.80 millionViewListenView Earnings Details
2/26/2015Q314$0.09$0.08$29.30 million$30.40 millionViewN/AView Earnings Details
10/30/2014Q214$0.06$0.05$25.46 million$25.40 millionViewN/AView Earnings Details
7/31/2014Q2$0.05$0.05$26.00 million$26.96 millionViewN/AView Earnings Details
5/1/2014Q1 2014$0.04$25.89 millionViewN/AView Earnings Details
2/27/2014Q413($0.02)$0.05$28.20 million$27.90 millionViewN/AView Earnings Details
10/31/2013Q313$0.01$0.05$26.10 million$25.10 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.01)$26.09 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.08$28.30 million$26.10 millionViewN/AView Earnings Details
2/28/2013Q4 2012$0.02$0.02ViewN/AView Earnings Details
11/1/2012Q312$0.08$26.40 million$26.10 millionViewN/AView Earnings Details
8/2/2012Q2 2012$0.08$0.04ViewN/AView Earnings Details
5/3/2012Q1 2012$0.08$0.04ViewN/AView Earnings Details
3/1/2012Q4 2011$0.08$0.05ViewN/AView Earnings Details
11/3/2011Q3 2011$0.08$0.02ViewN/AView Earnings Details
8/4/2011Q2 2011$0.08$0.07ViewN/AView Earnings Details
4/28/2011Q1 2011$0.10$0.08ViewN/AView Earnings Details
2/25/2011Q4 2010$0.09$0.09ViewN/AView Earnings Details
11/3/2010Q3 2010$0.08$0.11ViewN/AView Earnings Details
8/5/2010Q2 2010$0.09$0.07ViewN/AView Earnings Details
4/29/2010Q1 2010$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.10$0.08ViewN/AView Earnings Details
11/4/2009Q3 2009$0.07$0.05ViewN/AView Earnings Details
8/6/2009Q2 2009$0.04$0.02ViewN/AView Earnings Details
4/30/2009Q1 2009$0.04$0.06ViewN/AView Earnings Details
2/26/2009Q4 2008$0.07$0.06ViewN/AView Earnings Details
11/5/2008Q3 2008$0.06$0.05ViewN/AView Earnings Details
8/11/2008Q2 2008$0.09$0.06ViewN/AView Earnings Details
5/1/2008Q1 2008$0.07$0.07ViewN/AView Earnings Details
2/28/2008Q4 2007$0.08$0.08ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Harvard Bioscience (NASDAQ:HBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Harvard Bioscience (NASDAQ HBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 68.03%
Insider Trading History for Harvard Bioscience (NASDAQ:HBIO)
Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ HBIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2018George UvegesDirectorSell22,250$4.58$101,905.00View SEC Filing  
3/9/2018Jeffrey DucheminCEOSell87,022$4.53$394,209.66View SEC Filing  
3/7/2018George UvegesDirectorSell35,054$4.61$161,598.94View SEC Filing  
3/7/2018Robert E. GagnonCFOSell97,087$4.62$448,541.94View SEC Filing  
6/12/2017Jeffrey DucheminCEOBuy22,000$2.76$60,720.00View SEC Filing  
6/8/2017James W. GreenDirectorBuy7,712$2.55$19,665.60View SEC Filing  
5/26/2017Robert E. GagnonCFOBuy1,000$2.33$2,330.00View SEC Filing  
5/25/2017Earl R. LewisDirectorBuy12,238$2.35$28,759.30View SEC Filing  
5/24/2017Earl R. LewisDirectorBuy10,000$2.38$23,800.00View SEC Filing  
2/7/2017David GreenDirectorSell3,239$3.25$10,526.75View SEC Filing  
2/6/2017David GreenDirectorSell1,288$3.25$4,186.00View SEC Filing  
12/6/2016Earl R. LewisDirectorSell23,088$2.42$55,872.96View SEC Filing  
11/3/2016Jeffrey DucheminCEOBuy15,000$2.42$36,300.00View SEC Filing  
11/3/2016Robert E. GagnonCFOBuy25,000$2.34$58,500.00View SEC Filing  
12/10/2015Jeffrey DucheminCEOBuy10,000$3.37$33,700.00160,210View SEC Filing  
12/3/2015George UvegesDirectorBuy3,000$3.32$9,960.0067,171View SEC Filing  
11/9/2015Robert E GagnonCFOBuy3,000$3.08$9,240.0066,221View SEC Filing  
9/2/2015Jeffrey DucheminCEOBuy2,000$4.41$8,820.00150,210View SEC Filing  
9/1/2015John F KennedyDirectorBuy2,000$4.33$8,660.00177,330View SEC Filing  
7/17/2015David GreenDirectorSell17,103$5.26$89,961.78View SEC Filing  
7/14/2015David GreenDirectorSell51,597$5.28$272,432.16View SEC Filing  
4/23/2015David GreenDirectorSell118,500$6.03$714,555.00View SEC Filing  
4/22/2015David GreenDirectorSell123,997$6.23$772,501.31View SEC Filing  
4/17/2015David GreenDirectorSell42,503$6.55$278,394.65View SEC Filing  
4/14/2015David GreenDirectorSell80,168$6.61$529,910.48View SEC Filing  
2/9/2015David GreenDirectorSell48,712$5.25$255,738.00View SEC Filing  
12/30/2014David GreenDirectorSell16,173$5.25$84,908.25View SEC Filing  
12/29/2014David GreenDirectorSell100,167$5.25$525,876.75View SEC Filing  
12/22/2014David GreenDirectorSell80,202$5.02$402,614.04View SEC Filing  
11/19/2014David GreenDirectorSell10,000$4.95$49,500.00View SEC Filing  
10/31/2014David GreenDirectorSell117,654$4.97$584,740.38View SEC Filing  
6/16/2014Robert E GagnonCFOBuy5,000$3.86$19,300.00View SEC Filing  
5/29/2014Neal J HarteDirectorSell12,317$3.82$47,050.94View SEC Filing  
4/9/2014David GreenDirectorSell27,540$4.47$123,103.80View SEC Filing  
4/8/2014David GreenDirectorSell66,090$4.48$296,083.20View SEC Filing  
4/3/2014David GreenDirectorSell63,501$4.63$294,009.63View SEC Filing  
8/27/2013Chane GrazianoMajor ShareholderBuy60,000$5.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Harvard Bioscience (NASDAQ HBIO) News Headlines

Source:
DateHeadline
 Harvard Bioscience, Inc. (HBIO) Given Average Recommendation of "Strong Buy" by Analysts Harvard Bioscience, Inc. (HBIO) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 23 at 5:15 PM
Harvard Bioscience (HBIO) vs. Integra lifesciences (IART) Head to Head SurveyHarvard Bioscience (HBIO) vs. Integra lifesciences (IART) Head to Head Survey
www.americanbankingnews.com - May 17 at 9:19 PM
Head to Head Review: Harvard Bioscience (HBIO) versus Coherent (COHR)Head to Head Review: Harvard Bioscience (HBIO) versus Coherent (COHR)
www.americanbankingnews.com - May 17 at 2:23 PM
Harvard Bioscience (HBIO) and Mettler Toledo (MTD) Critical ComparisonHarvard Bioscience (HBIO) and Mettler Toledo (MTD) Critical Comparison
www.americanbankingnews.com - May 16 at 11:11 AM
Mettler Toledo (MTD) and Harvard Bioscience (HBIO) Critical AnalysisMettler Toledo (MTD) and Harvard Bioscience (HBIO) Critical Analysis
www.americanbankingnews.com - May 9 at 3:12 AM
Harvard Bioscience (HBIO) Stock Rating Lowered by ValuEngineHarvard Bioscience (HBIO) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
 Harvard Bioscience (HBIO) Given Average Recommendation of "Strong Buy" by Analysts Harvard Bioscience (HBIO) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 5 at 3:33 AM
Harvard Bioscience (HBIO) Rating Lowered to Hold at Zacks Investment ResearchHarvard Bioscience (HBIO) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 3 at 11:51 PM
Harvard Bioscience (HBIO) Releases  Earnings Results, Meets ExpectationsHarvard Bioscience (HBIO) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - May 3 at 7:29 PM
ValuEngine Upgrades Harvard Bioscience (HBIO) to "Strong-Buy"ValuEngine Upgrades Harvard Bioscience (HBIO) to "Strong-Buy"
www.americanbankingnews.com - May 3 at 4:24 PM
Harvard Biosciences (HBIO) CEO Jeffrey Duchemin on Q1 2018 Results - Earnings Call TranscriptHarvard Bioscience's (HBIO) CEO Jeffrey Duchemin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:46 AM
Edited Transcript of HBIO earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of HBIO earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 9:46 AM
Harvard Bioscience: 1Q Earnings SnapshotHarvard Bioscience: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:46 AM
Harvard Bioscience Reports First Quarter 2018 Financial ResultsHarvard Bioscience Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 4:07 PM
Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants to Enhance Neuroscience ResearchHarvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants to Enhance Neuroscience Research
finance.yahoo.com - May 2 at 9:49 AM
Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology MarketHarvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market
finance.yahoo.com - May 2 at 9:49 AM
Comparing Harvard Bioscience (HBIO) and Agilent Technologies (A)Comparing Harvard Bioscience (HBIO) and Agilent Technologies (A)
www.americanbankingnews.com - April 26 at 11:15 PM
Zacks.com featured highlights include: TheStreet, Joint, Harvard Bioscience and CPIZacks.com featured highlights include: TheStreet, Joint, Harvard Bioscience and CPI
finance.yahoo.com - April 25 at 4:14 PM
Should You Be Content With Harvard Bioscience Inc’s (NASDAQ:HBIO) Earnings Growth?Should You Be Content With Harvard Bioscience Inc’s (NASDAQ:HBIO) Earnings Growth?
finance.yahoo.com - April 25 at 10:09 AM
Critical Survey: Accelerate Diagnostics (AXDX) versus Harvard Bioscience (HBIO)Critical Survey: Accelerate Diagnostics (AXDX) versus Harvard Bioscience (HBIO)
www.americanbankingnews.com - April 25 at 1:18 AM
 Harvard Bioscience, Inc. (HBIO) Given $9.00 Average Price Target by Brokerages Harvard Bioscience, Inc. (HBIO) Given $9.00 Average Price Target by Brokerages
www.americanbankingnews.com - April 19 at 11:32 PM
Harvard Bioscience (HBIO) to Release Quarterly Earnings on WednesdayHarvard Bioscience (HBIO) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 8:16 PM
Comparing Harvard Bioscience (HBIO) & Horiba (HRIBF)Comparing Harvard Bioscience (HBIO) & Horiba (HRIBF)
www.americanbankingnews.com - April 17 at 3:10 AM
Benchmark Analysts Give Harvard Bioscience (HBIO) a $10.00 Price TargetBenchmark Analysts Give Harvard Bioscience (HBIO) a $10.00 Price Target
www.americanbankingnews.com - April 16 at 9:16 AM
Harvard Bioscience (HBIO) Lifted to Hold at ValuEngineHarvard Bioscience (HBIO) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
Harvard Bioscience (HBIO) Upgraded at TheStreetHarvard Bioscience (HBIO) Upgraded at TheStreet
www.americanbankingnews.com - April 14 at 11:49 AM
Can The Uptrend Continue for Harvard Bioscience (HBIO)?Can The Uptrend Continue for Harvard Bioscience (HBIO)?
www.zacks.com - April 12 at 10:57 AM
Harvard Bioscience (HBIO) Upgraded to Buy at ValuEngineHarvard Bioscience (HBIO) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 1:55 PM
 Brokerages Set $9.00 Price Target for Harvard Bioscience, Inc. (HBIO) Brokerages Set $9.00 Price Target for Harvard Bioscience, Inc. (HBIO)
www.americanbankingnews.com - April 1 at 5:31 PM
Edited Transcript of HBIO earnings conference call or presentation 1-Mar-18 9:30pm GMTEdited Transcript of HBIO earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:54 AM
Harvard Bioscience, Inc. (HBIO) Director George Uveges Sells 22,250 SharesHarvard Bioscience, Inc. (HBIO) Director George Uveges Sells 22,250 Shares
www.americanbankingnews.com - March 15 at 10:26 PM
Harvard Bioscience, Inc. (HBIO) Director George Uveges Sells 35,054 SharesHarvard Bioscience, Inc. (HBIO) Director George Uveges Sells 35,054 Shares
www.americanbankingnews.com - March 12 at 7:57 PM
Harvard Bioscience, Inc. (HBIO) CFO Sells $448,541.94 in StockHarvard Bioscience, Inc. (HBIO) CFO Sells $448,541.94 in Stock
www.americanbankingnews.com - March 12 at 7:38 PM
Insider Selling: Harvard Bioscience, Inc. (HBIO) CEO Sells 87,022 Shares of StockInsider Selling: Harvard Bioscience, Inc. (HBIO) CEO Sells 87,022 Shares of Stock
www.americanbankingnews.com - March 12 at 7:38 PM
Harvard Bioscience (HBIO) Rating Increased to Buy at Zacks Investment ResearchHarvard Bioscience (HBIO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 9 at 12:43 AM
Harvard Bioscience (HBIO) Announces Quarterly  Earnings ResultsHarvard Bioscience (HBIO) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 2 at 11:56 AM
Royce & Associates LP Decreases Holdings in Harvard Bioscience, Inc. (HBIO)Royce & Associates LP Decreases Holdings in Harvard Bioscience, Inc. (HBIO)
www.americanbankingnews.com - March 2 at 10:44 AM
An Intrinsic Value Calculation For Harvard Bioscience Inc (NASDAQ:HBIO) Shows Investors Are OverpayingAn Intrinsic Value Calculation For Harvard Bioscience Inc (NASDAQ:HBIO) Shows Investors Are Overpaying
finance.yahoo.com - March 2 at 9:50 AM
Harvard Bioscience posts 4Q profitHarvard Bioscience posts 4Q profit
finance.yahoo.com - March 2 at 9:50 AM
Harvard Bioscience (HBIO) & Mindray Medical International (MR) Head to Head ComparisonHarvard Bioscience (HBIO) & Mindray Medical International (MR) Head to Head Comparison
www.americanbankingnews.com - March 1 at 7:16 PM
Harvard Bioscience Reports Fourth Quarter and Year-End 2017 ResultsHarvard Bioscience Reports Fourth Quarter and Year-End 2017 Results
finance.yahoo.com - March 1 at 4:22 PM
Harvard Bioscience (HBIO) Set to Announce Quarterly Earnings on WednesdayHarvard Bioscience (HBIO) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM
Head to Head Review: Invivo Therapeutics (NVIV) & Harvard Bioscience (HBIO)Head to Head Review: Invivo Therapeutics (NVIV) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - February 12 at 5:12 AM
Harvard Bioscience (HBIO) & Invivo Therapeutics (NVIV) Head to Head ContrastHarvard Bioscience (HBIO) & Invivo Therapeutics (NVIV) Head to Head Contrast
www.americanbankingnews.com - February 9 at 9:10 PM
Waters (WAT) vs. Harvard Bioscience (HBIO) Critical ContrastWaters (WAT) vs. Harvard Bioscience (HBIO) Critical Contrast
www.americanbankingnews.com - February 7 at 1:12 AM
Analyzing Intuitive Surgical (ISRG) & Harvard Bioscience (HBIO)Analyzing Intuitive Surgical (ISRG) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - February 6 at 12:43 PM
Harvard Bioscience closes Data Sciences purchaseHarvard Bioscience closes Data Sciences purchase
seekingalpha.com - January 31 at 8:00 PM
Harvard Bioscience Completes Acquisition of Data Sciences InternationalHarvard Bioscience Completes Acquisition of Data Sciences International
feeds.benzinga.com - January 31 at 7:07 PM
Harvard Bioscience, Inc. (HBIO) Short Interest Down 27.7% in JanuaryHarvard Bioscience, Inc. (HBIO) Short Interest Down 27.7% in January
www.americanbankingnews.com - January 29 at 1:40 AM
Hologic (HOLX) and Harvard Bioscience (HBIO) Critical AnalysisHologic (HOLX) and Harvard Bioscience (HBIO) Critical Analysis
www.americanbankingnews.com - January 27 at 11:26 AM

SEC Filings

Harvard Bioscience (NASDAQ:HBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Harvard Bioscience (NASDAQ:HBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Harvard Bioscience (NASDAQ HBIO) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.